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Abstract
Background: Family studies and heritability estimates provide evidence for a genetic contribution to variation in the
human life span.
Methods: We conducted a genome wide association study (Affymetrix 100K SNP GeneChip) for longevity-related traits
in a community-based sample. We report on 5 longevity and aging traits in up to 1345 Framingham Study participants
from 330 families. Multivariable-adjusted residuals were computed using appropriate models (Cox proportional hazards,
logistic, or linear regression) and the residuals from these models were used to test for association with qualifying SNPs
(70, 987 autosomal SNPs with genotypic call rate ≥80%, minor allele frequency ≥10%, Hardy-Weinberg test p ≥ 0.001).
Results:  In family-based association test (FBAT) models, 8 SNPs in two regions approximately 500 kb apart on
chromosome 1 (physical positions 73,091,610 and 73, 527,652) were associated with age at death (p-value < 10-5). The
two sets of SNPs were in high linkage disequilibrium (minimum r2 = 0.58). The top 30 SNPs for generalized estimating
equation (GEE) tests of association with age at death included rs10507486 (p = 0.0001) and rs4943794 (p = 0.0002),
SNPs intronic to FOXO1A, a gene implicated in lifespan extension in animal models. FBAT models identified 7 SNPs and
GEE models identified 9 SNPs associated with both age at death and morbidity-free survival at age 65 including rs2374983
near PON1. In the analysis of selected candidate genes, SNP associations (FBAT or GEE p-value < 0.01) were identified
for age at death in or near the following genes: FOXO1A, GAPDH, KL, LEPR, PON1, PSEN1, SOD2, and WRN. Top ranked
SNP associations in the GEE model for age at natural menopause included rs6910534 (p = 0.00003) near FOXO3a and
rs3751591 (p = 0.00006) in CYP19A1. Results of all longevity phenotype-genotype associations for all autosomal SNPs
are web posted at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
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Conclusion: Longevity and aging traits are associated with SNPs on the Affymetrix 100K GeneChip. None of the
associations achieved genome-wide significance. These data generate hypotheses and serve as a resource for replication
as more genes and biologic pathways are proposed as contributing to longevity and healthy aging.
Background
Genetic factors associated with human longevity and
healthy aging remain largely unknown. Heritability esti-
mates of longevity derived from twin registries and large
population-based samples suggest a significant but mod-
est genetic contribution to the human lifespan (heritabil-
ity ~15 to 30%) [1-4]. However, genetic influences on
lifespan may be greater once an individual achieves age 60
years [5]. Moreover, the reported magnitude of the genetic
contribution to other important aspects of aging such as
healthy physical aging (wellness)[6], physical perform-
ance [7,8], cognitive function [9], and bone aging [10] are
much larger. Both exceptional longevity and a healthy
aging phenotype have been linked to the same region on
chromosome 4 [11,12], suggesting that although longev-
ity per se and healthy aging are different phenotypes, they
may share some common genetic pathways.
A number of potential candidate genes in a variety of bio-
logical pathways have been associated with longevity in
model organisms. Genes involved in the regulation of
DNA repair and genes in the evolutionarily conserved
insulin/insulin-like growth factor signaling pathway
[13,14] are emerging as holding great promise in the
future elucidation of the underlying physiology control-
ling lifespan. Many of these genes have human homologs
and thus have potential to provide insights into human
longevity [15-20]. Although numerous candidate genes
have been proposed, studies in humans are limited and
initial findings often fail replication [21,22]. More
recently genome-wide association studies (GWAS) have
become feasible and offer a more comprehensive and
untargeted approach to detect genes with modest pheno-
typic effects that underlie common complex conditions
[23].
We had the opportunity to use the Framingham Heart
Study (FHS) Affymetrix 100K SNP genotyping resource
for a GWAS of longevity and aging-related phenotypes.
The FHS offers the unique advantage of a longitudinal
family-based community sample with participants who
have been well-characterized throughout adulthood with
respect to prospectively ascertained risk factors and dis-
eases and continuously followed until death. We report
several strategies for 100K SNP associations: 1) a simple
low p-value SNP ranking strategy; 2) SNP selection due to
associations with more than one related phenotype; and
3) SNP associations within candidate genes and regions
previously reported to be associated with longevity in
model organisms or humans.
Methods
Study sample
The genotyped study sample is comprised of 1345 Origi-
nal cohort (n = 258) and Offspring (n = 1087) partici-
pants who are members of the 330 largest FHS families.
The Overview [24] provides further details of this sample.
With respect to aging and longevity traits, 149 deaths
occurred at a mean age at death of 83 years (range 46 to
99 years) and 713 participants achieved age 65 years or
greater. The Boston University Medical Center Institu-
tional Review Board approved the examination content of
Original Cohort and Offspring examinations. All partici-
pants provided written informed consent at every exami-
nation including consent for genetic studies.
Longevity and aging phenotype definitions and residual 
creation
Age at death
Both the Original Cohort and the Offspring Cohort
remain under continuous surveillance and all deaths that
occurred prior to January 1, 2005 were included in this
study. Deaths were identified using multiple strategies
including routine participant contact for research exami-
nations or health history updates, surveillance at the local
hospital, search of obituaries in the local newspaper, and
if needed through use of the National Death Index. Death
certificates were routinely obtained and all hospital and
nursing home records prior to death and autopsy reports
(if performed) were requested. In addition, if there was
insufficient information to determine a cause of death,
the next of kin were interviewed by a senior investigator.
All records pertinent to the death were reviewed by an
endpoint panel comprised of three senior investigators.
The date and cause of death (classified as due to coronary
heart disease, stroke, other cardiovascular disease [CVD],
cancer, other causes, or unknown cause) was recorded.
Cox proportional hazards models were used to generate
martingale residuals using the PHREG procedure in SAS
to perform the regression analysis of survival time from
age at study entry to age at death. Models were sex-specific
and adjusted for 1) birth cohort and 2) birth cohort, edu-
cation, current smoking status (yes/no), obesity (body
mass index ≥30 kg/m2), hypertension (blood pressure
≥140/90 mmHg or on antihypertensive treatment), ele-
vated cholesterol (cholesterol > 239 mg/dL), diabetesBMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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(fasting blood sugar ≥126 mg/dL, random blood sugar of
≥200 mg/dL, or use of insulin or oral hypoglycemic
agents) and comorbidity defined as CVD and cancer. Birth
cohort was defined as a categorical variable for all regres-
sion models with the following categories based on year
of birth: birth year prior to 1900, 1900 to 1909, 1910 to
1919, 1920 to 1929, 1930 to 1939, 1940 to 1949, and
1950 and later. All covariates were measured at study
entry. Residuals from Original Cohort and Offspring par-
ticipants were pooled.
Morbidity-free survival at age 65 years
Morbidity-free survival was defined as achieving age 65
years free of CVD, dementia, and cancer. CVD events
included angina pectoris, coronary insufficiency, myocar-
dial infarction, heart failure, stroke, transient ischemic
attack (TIA), intermittent claudication and coronary or
CVD death. Suspected CVD events were reviewed by a
panel of three investigators who adjudicated events using
previously established criteria in place since study incep-
tion [25]. A separate panel of study neurologists deter-
mined the presence of stroke or TIA and a team of at least
one neurologist and one neuropsychologist determined
the presence of dementia. Two independent reviewers
examined records for all cancers, and the vast majority of
cancer cases were microscopically confirmed with pathol-
ogy reports.
Logistic regression models were used to generate deviance
residuals. Models were sex-specific and adjusted for 1)
birth cohort and 2) birth cohort, education, current smok-
ing status, obesity, hypertension, elevated cholesterol, and
diabetes. Covariates were defined as above for age at
death. All covariates were measured at the examination
closest to the participant attaining age 65 years using a 5
year window around age 65 years. Residuals from Origi-
nal Cohort and Offspring participants were pooled.
Age at natural menopause
Natural menopause occurred after a woman had ceased
menstruating naturally for one year and the age at natural
menopause was the self-reported age at last menstruation.
Mean age at natural menopause was similar in Original
Cohort and Offspring women and the distribution of nat-
urally menopausal ages in women in the 330 FHS families
was similar to that of women in all 1643 FHS families
[26,27]. The mean age at natural menopause in women in
the 100K sample was 50.2 years (range 38 to 57 years) in
Original Cohort women and 49.1 years (range 29 to 60
years) in Offspring women.
Crude age at natural menopause and standardized residu-
als from multiple linear regressions in SAS [28] that
adjusted age at natural menopause for covariates of inter-
est were used as traits for analysis. Covariates were
obtained at all attended examinations prior to the onset of
menopause and included mean number of cigarettes
smoked per day, mean body mass index, parity (0 versus
1 or more live births), and generation (Original Cohort vs.
Offspring).
Walking speed
Walking speed was measured on Original Cohort partici-
pants at examination 27 (January 2002 through Decem-
ber 2003, mean age of Original Cohort at exam 27: 86.7
years) and Offspring participants attending an ancillary
study to examination 7 (1999 to 2004, mean age at exam:
62.0 years). Trained technicians timed participants walk-
ing at their normal pace on a four meter course twice and
subsequently asked participants to repeat the course walk-
ing at a rapid pace. The mean timed fast walk among Off-
spring participants in the 100K genotyping sample was
2.44 seconds (standard deviation 0.89). The timed fast
walk was used for analysis. Sex-specific linear regression
was used to generate residuals adjusted for age and height
measured at the time of the walk.
Biologic age by osseographic scoring system
An osseographic scoring system (OSS) was applied to
hand radiographs obtained on original cohort (1967 to
1969, mean age 58.7 years) and offspring participants
(1992 to 1993, mean age 51.6 years) [10]. Biologic age
was then defined as the standardized residual between the
OSS predicted age and the actual age. Biologic age defined
by this system predicted mortality [10,29], was very herit-
able (h2 = 0.57 ± 0.06), and a genome-wide linkage anal-
ysis was performed with LOD scores >1.8 present on
chromosomes 3q, 11p, 16q, and 21q [10]. Sex- and
cohort-specific ranked residuals generated from linear
regression of age on log-OSS adjusted for height, body
mass index, menopause, and estrogen therapy, were used
for analysis.
Genotyping
Affymetrix 100K SNP GeneChip genotyping and the
Marshfield STR genotyping performed by the Mammalian
Genotyping Service http://research.marshfieldclinic.org/
genetics are described in the Overview paper [24].
Statistical analysis
The statistical methods for genome-wide linkage and
association analyses are described in the Overview [24].
Association
All residual traits described above as well as the additional
traits listed in Table 1 were computed using Cox propor-
tional hazards with martingale residuals for survival traits,
logistic regression with deviance residuals for dichoto-
mous traits, and linear regression with standard residuals
for quantitative traits. The full set of FHS participants withBMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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the phenotype were used to create the residuals. The resid-
uals were used to test for association between the geno-
typed subset of individuals and the SNPs using additive
family-based association test (FBAT) and generalized esti-
mating equations (GEE) models as described in the Over-
view [24]. A total of 70,987 autosomal SNPs met the
criteria of genotypic call rate ≥80%, minor allele fre-
quency ≥10%, Hardy-Weinberg test p ≥ 0.001, and ≥10
informative families for FBAT. The number of tests with
an FBAT p < 0.001, p < 0.0001, and p < 0.00001 for all
phenotypes was similar to what would be expected under
the assumptions that the 70,987 tested SNPs were inde-
pendent and there were no true associations. The GEE
tests tended to give an excess of very small p-values over
what would be expected under these assumptions.
SNP prioritization
We used several strategies to prioritize SNPs associated
with longevity and aging traits. First, we used an untar-
geted approach whereby the top 50 SNP associations
ranked according to the strength of the p-value for each
trait were examined. Next, we explored the consistency of
SNP associations across related sets of traits chosen a pri-
ori (trait set one: age at death and morbidity-free survival
at age 65 years; trait set two: biologic age and walking
speed). Trait set one was chosen based upon linkage data
in humans demonstrating that both longevity and a
healthy aging trait were linked to the same region on chro-
mosome 4 raising the hypothesis that the two phenotypes
may share common genetic pathways [11,12]. The traits
in set two reflect aging with good physical functioning
and thus we postulated that biologic age and walking
speed may have genetic variants in common. We also
investigated SNP associations in candidate genes and
regions reported to be associated with longevity identified
from established databases including NCBI [14] using the
search term "longevity" and the Science of Aging Knowl-
edge Environment genes/intervention database http://
sageke.sciencemag.org/cgi/genesdb[30] choosing genes
potentially related to lifespan in humans.
The SNPs were annotated using the UCSC genome
browser tables using the May 2004 assembly http://
genome.ucsc.edu/[31,32]. All genes within 60 kb of the
top ranked SNPs were identified.
Results
The longevity and aging traits available in the FHS 100K
SNP resource are listed in Table 1. In this report, we con-
sider only five of the traits listed in Table 1: multivariable-
adjusted age at death, morbidity-free survival at age 65
years, age at natural menopause, walking speed, and bio-
logic age by OSS. These traits include a pooled sample of
Original Cohort and Offspring participants, with the
exception of walking speed, which is reported in Off-
spring participants only. Details of the sample size and
covariate adjustment for each trait are provided in Table 1.
For each of the five phenotypes, Table 2a and 2b provides
the top five SNPs ranked in order by lowest p-value for the
GEE and FBAT models (all associations can be viewed on
the web http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?id=phs000007). If multiple SNPs in linkage
disequilibrium (LD r2 > 0.80) were included in the top 5,
additional SNPs were included until a set of 5 independ-
ent associations were listed. Eight SNPs on chromosome
1 were associated with age at death in the FBAT analysis;
all with p-value < 10-4 and two with p-value < 10-5. The 8
SNPs consisted of two sets of SNPs (rs10493513,
rs10493514, rs6689491, rs6657082, rs1405051) and
(rs10493515, rs10493518, rs10493517), clustered in two
regions approximately 500 kb apart. There was exception-
ally high LD across this 500 kb region: the minimum r2
between pairs of the eight SNPs was 0.58. The nearest
genes in this region existing in public databases were >500
kb from any of these SNPs [31,32].
There were several additional associations not listed in
Table 2a and 2b that were of interest. For age at death in
the GEE analysis, SNP associations ranked numbers 9 and
13 were rs10507486 (p-value 0.000128) and rs4943794
(p-value 0.000277), both are intronic FOXO1A SNPs. For
age at natural menopause, top ranked SNP associations in
the GEE model included number 11, rs6910534 (p =
0.00003) near FOXO3a and number 18, rs3751591 (p =
0.00006) in CYP19A1.
Table 2c presents the LOD scores ≥2.0 and the corre-
sponding 1.5-LOD support interval from genome-wide
linkage for the three quantitative aging traits. None of the
regions overlapped with SNPs associated with these aging
traits in the FBAT and GEE analyses. Of note for biologic
age by OSS the linkage peak on chromosome 21 con-
firmed a prior Framingham Study report using a genome-
wide scan with 401 microsatellite markers [10].
Table 3 provides all SNP associations with a GEE or FBAT
p < 0.01 for both traits within the two pairs of related
traits. For age at death and morbidity-free survival at age
65 years, FBAT models identified 7 SNPs and GEE models
identified 9 SNPs associated with both traits including
rs2374983 near PON1 (Tables 3a and 3b). For biologic
age by OSS and walking speed, 13 SNPs in FBAT models
and 6 SNPs in GEE models were associated with both
traits (Tables 3c and 3d).
We identified from the literature 79 potential candidate
genes and regions associated with longevity (see Addi-
tional file 1 for listing). Of these, 12 genes had no SNPs
and 67 genes had 1 to 45 SNPs within 60 kb of the geneBMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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on the 100K Affymetrix GeneChip. There were 2036 SNPs
in the LGV1 region on chromosome 4 previously linked
to exceptional longevity [11]. Table 4 shows the candidate
genes with SNPs associated with an FBAT or GEE p-value
< 0.01 for age at death including: FOXO1a, GAPDH, KL,
LEPR, PON1, PSEN1, SOD2, and WRN and for morbidity-
free survival at 65 years including:GHR, LEPR, MORF4L1,
PON1, PTH, and WRN. Biologic age by OSS shared 2 SNPs
in common with age at death: rs4943794 intronic to
FOXO1a and rs911847 near SOD2.
Discussion
To our knowledge, this is the first dense GWAS of longev-
ity and aging traits in a community-based sample of
adults from two generations of the same families. Over
1300 men and women have detailed longevity and aging-
Table 1: Aging and Longevity Phenotypes for Framingham Heart Study 100K Project
Exam cycle(s)
Phenotype Subgroup
• Trait (variable name on the 
website*)
Number of Traits N (MV**) Offspring / Original 
Cohort
Adjustment
Survival Traits: Cox regression
Survival
• Age at death (1. deathageX, 2. 
deathageMV)
2 1345 (1166) Cohort & Offspring 
pooled
Cox regression
Sex-specific
1. birth cohort
2. multivariable adjusted for birth cohort, education, 
smoking, obesity (BMI ≥ 30), CVD risk factors, co-morbidity 
measured at exam 1
Categorical traits: Logistic regression
• Survival past the ALE (1. 
deathpastALEX, 2. deathpastALEMV)
2 1345 (1166) Cohort & Offspring 
pooled
Logistic regression
Sex-specific
1. birth cohort
2. multivariable adjusted for birth cohort, education, 
smoking, obesity (BMI ≥ 30), CVD risk factors, co-morbidity 
measured at exam 1
Morbidity-free survival (free of 
CVD, cancer and dementia)
• At age 65 years (1. 
morbidityfree65X, 2. 
morbidityfree65MVX)
2 558 (558) Cohort & Offspring 
pooled, exams closest to 
age 65 years
Logistic regression
Sex-specific
1. birth cohort
2. multivariable adjusted for birth cohort, education, 
smoking, obesity, CVD risk factors measured at exam closest 
to age 65 years (within a 5 year horizon)
Quantitative Traits: Linear regression
Reproductive Aging
• Age at natural menopause (1. 
menoageX, 2. menoageMVX)
2 438 (378) Cohort & Offspring 
pooled, women only
Linear regression
1. crude
2. multivariable adjusted for smoking, BMI, parity, generation 
(measured at exams prior to menopause)
Cognitive function
• MMSE at age 65 years (1. MMSE65X, 
2. MMSE65MVX)
• MMSE at the specified Offspring 
exam (1. MMSE5X, 2. MMSE5MVX, 1. 
MMSE7X, 2. MMSE7MV, 1. 
MMSE5to7X, 2. MMSE5to7MVX)
2 593 (462) Cohort & Offspring 
pooled, exams at age 65
Linear regression
Sex-specific
1. birth cohort
2. multivariable adjusted for birth cohort, education, FSRP 
measured at exam closest to age 65 years (5 year horizon)
6 1038 (913) Exam 5
Exam 7
Exam 5 & 7
average score
Linear regression
Sex-specific
1. birth cohort
2. multivariable adjusted for birth cohort, education, FSRP; 
covariates measured at the specified exam
Physical Performance
• Hand grip (2. handgrip7x, 2. 
handgrips727x)
• Walking speed (2. walkingspeed7x, 2. 
walkingspeed727x)
6 764 Exam 7
Exam 7 and Exam 27
Linear regression
Sex-specific‡
1. age
2. multivariable adjusted for age, height, weight at the 
specified exam
Biologic Age by Osseographic 
Scoring System (1. deltaOSSr, delta 
OSSrf, deltaOSSrm)
3 714 Offspring and Cohort 
pooled
exam 6/7 and exam 22
Linear regression
Sex- and cohort-specific ranked residuals§
1. multivariable adjusted for age, height, BMI, menopause, 
estrogen use
Residuals from these models were used as traits to test for association with SNP genotypes.
* The number preceding the variable name refers to the covariate adjustment in the last column of the table. The website with all results is found at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007; ** MV = N for multivariable trait
‡ cohort- and sex-specific residuals for traits that included both cohort and offspring; §cohort-specific for traits limited to one sex
ALE = average life expectancy, BMI = body mass index, Co-morbidity = cardiovascular disease and cancer, CVD = cardiovascular disease, FSRP = Framingham stroke risk 
profile, MMSE = mini-mental state exam, Risk factors = hypertension, diabetes, elevated cholesterolBMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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Table 2: Aging and Longevity Phenotypes† for FHS 100K Project: Results of Association and Linkage Analyses
2a. GEE, Top 5 p-values by Phenotype*
Trait SNP Chromosome Physical location GEE p-value FBAT p-value Gene Region (within 60 kb)
Age at death
rs1528753 11 90,523,987 8.1 × 10-8 0.024
rs2371208 7 81,982,510 2.6 × 10-6 0.031
rs10496799 2 139,261,401 1.4 × 10-5 0.735 NXPH2
rs10489006 4 31,444,987 3.6 × 10-5 0.078
rs3757354 6 16,235,386 6.4 × 10-5 0.316 MYLIP
Morbidity-free survival at age 65
rs1412337 1 165,350,299 1.8 × 10-9 0.505 DPT
rs32566 5 5,845,507 1.9 × 10-9 0.323
rs10484246 6 9,559,183 8.4 × 10-8 0.928
rs4831837 8 12,756,234 4.7 × 10-7 0.182
rs2639889 16 59,680,648 9.4 × 10-7 0.903
Age at natural menopause‡
rs10496265 2 81,580,466 1.1 × 10-8 0.001
rs10496262* 2 81,662,782 3.3 × 10-7 0.005
rs958672 2 154,896,075 1.9 × 10-6 0.087 GALNT13
rs291353 1 232,046,939 5.5 × 10-6 0.035 GNG4
rs726336 5 163,911,906 1.1 × 10-5 0.125
Walking speed exam 7
rs7137869 12 118,452,366 6.3 × 10-7 0.009 CCDC60
rs7662116 4 154,375,569 1.9 × 10-5 0.016
rs7972859* 12 118,452,765 2.5 × 10-5 0.005 CCDC60
rs9318312 13 74,489,506 5.8 × 10-5 0.266
rs1994854 4 78,124,824 9.4 × 10-5 0.280
rs7718104 5 122,183,258 1.2 × 10-4 0.011 SNX2
Biologic age by osseographic scoring system
rs1463605 12 30,005,150 7.0 × 10-8 5.3 × 10-4
rs7176093 15 84,170,434 7.4 × 10-6 0.005 KLHL25
rs3772255 3 157,585,436 8.2 × 10-6 0.085 KCNAB1
rs726846 5 136,099,953 1.1 × 10-5 0.003
rs646983 13 29,413,553 1.2 × 10-5 0.003
2b. FBAT, Top 5 p-values by Phenotype*
Trait SNP Chromosome Physical location GEE p-value FBAT p-value Gene Region (within 60 kb)
Age at death
rs10493513 1 73,091,610 0.640 1.5 × 10-6
rs10493514* 1 73,092,533 0.623 2.8 × 10-6
rs6689491* 1 73,064,050 0.205 2.0 × 10-5
rs10493515 1 73,527,652 0.225 2.3 × 10-5
rs10493518* 1 73,572,652 0.191 3.6 × 10-5
rs10493517* 1 73,570,372 0.215 4.2 × 10-5
rs6657082* 1 73,065,349 0.224 5.5 × 10-5
rs10498263 14 19,285,288 0.310 8.3 × 10-5 OR4Q3
OR4M1
rs1915501 4 28,612,632 0.383 1.1 × 10-4
rs1405051* 1 73,060,505 0.176 1.4 × 10-4
rs6459623 6 18,634,791 0.604 1.5 × 10-4 IBRDC2BMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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Morbidity-free survival at age 65
rs10509200 10 65,296,567 0.613 7.0 × 10-5
rs965036 6 20,099,022 0.550 8.6 × 10-5
rs720565 6 136,834,657 0.014 9.8 × 10-5 MAP7
rs1192372 2 84,923,204 0.094 9.9 × 10-5
rs10505239 8 115,976,403 0.141 1.3 × 10-4
Age at natural menopause†
rs959702 10 2,139,260 0.003 1.4 × 10-5
rs7165378 15 69,478,558 0.006 6.4 × 10-5
rs997161 10 130,876,127 0.074 8.6 × 10-5
rs165284 1 91,235,574 0.006 8.6 × 10-5 ZNF644
rs2280585 3 64,882,324 0.884 1.1 × 10-4
Walking speed exam 7
rs4471448 11 86,760,972 0.175 3.8 × 10-6 TMEM135
rs336963 5 83,005,460 0.570 2.6 × 10-5 HAPLN1
rs7862683 9 18,257,947 0.001 4.9 × 10-5
rs9317757 13 68,458,430 0.252 7.8 × 10-5
rs10501636* 11 86,789,967 0.355 1.1 × 10-4
rs2340392 3 80,440,990 0.002 1.7 × 10-4
Biologic age by osseographic scoring system
rs1380703 2 57,852,938 0.008 1.1 × 10-5
rs324702 4 77,094,969 0.390 3.3 × 10-5 PPEF2
rs324735 4 77,062,193 0.096 7.6 × 10-5
rs1106184 2 10,914,125 0.006 8.8 × 10-5 PDIA6
rs604578 18 30,923,438 0.004 9.5 × 10-5 MAPRE2
2c Linkage¶ Peaks with LOD scores ≥ 2.0
Trait SNP closest to 
linkage peak
Chromosome Physical location 1.5 – LOD
support
interval start
1.5 – LOD
support
interval end
LOD score
Age at natural menopause
rs1371217 4 182,890,808 178,671,796 186,905,362 2.08
rs10509024 10 56,567,832 36,084,470 70,573,011 2.39
rs4793513 17 66,429,892 60,635,492 69,512,021 2.48
Walking speed, exam 7
rs2769261 1 113,278,949 107,080,550 144,332,709 2.30
rs921055 2 233,522,842 229,328,008 242,141,304 2.13
rs2602044 3 109,427,883 102,255,525 111,604,019 3.38
rs8011773 14 96,927,485 96,342,135 100,389,787 2.69
rs1362626 16 4,489,227 205,160 10,344,522 2.05
Biologic age by osseographic scoring system
rs353810 9 86,258,745 81,441,976 92,220,168 3.26
rs1203981 16 205,160 205,160 7,431,239 2.49
rs2248383 21 35,151,811 27,412,716 40,940,879 2.22
SNP criteria: Autosomal SNPs with genotypic call rate ≥ 80%, minor allele frequency ≥ 10%, Hardy-Weinberg test p > 0.001, and ≥10 informative 
families for FBAT
* For each phenotype SNPs are ranked by p-value. A SNP in LD (r2 > 0.8) with a higher ranked SNP, is identified with an asterisk. All SNPs for a 
phenotype are listed until 5 independent SNPs are identified. Thus, for some phenotypes more than 5 SNPs are listed. For the age at death trait, the 
FBAT analysis identified two areas on chromosome 1 in LD, with r2 = .5–.6 between the two regions and r2 of nearly 1.0 within the region.
† Multivariable-adjusted trait results are presented
‡Trait had <500 participants in the sample.
¶Results limited to traits presented
Table 2: Aging and Longevity Phenotypes† for FHS 100K Project: Results of Association and Linkage Analyses (Continued)BMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
Page 8 of 12
(page number not for citation purposes)
Table 3: All Significant SNP Associations (GEE or FBAT p-value < 0.01) for at least Two Traits
3a. FBAT: Age at Death and Morbidity-Free Survival at 65 years
Trait 1 Trait 2 SNP Chr Physical 
Position
Gene Trait 1 GEE 
p-value
Trait 1 FBAT 
p-value
Trait 2 GEE 
p-value
Trait 2 FBAT 
p-value
Age at 
Death
Morbidity-
free at 65 
rs6682403 1 234,743,324 0.849 0.004 0.106 0.004
rs10488907 4 113,669,709 ALPK1 0.452 0.008 0.336 0.009
rs17190837 9 13,391,548 0.010 0.009 0.097 0.004
rs4752977 11 47,257,005 MADD 0.736 0.008 0.002 0.009
rs10506274 12 80,103,932 0.531 0.001 0.989 0.001
rs2831154 21 28,059,331 0.323 0.008 0.358 0.006
rs243725* 21 28,060,803 0.264 0.007 0.359 0.008
*r2 > 0.80 with the preceding SNP
3b. GEE: Age at Death and Morbidity-Free Survival at 65 years
Trait 1 Trait 2 SNP Chr Physical 
Position
Gene Trait 1 GEE 
p-value
Trait 1 FBAT 
p-value
Trait 2 GEE 
p-value
Trait 2 FBAT 
p-value
Age at 
Death
Morbidity-
free at 65 
rs9308261 1 113,603,160 MAGI3 0.009 0.156 0.002 0.900
rs10490518 2 31,223,004 GALNT14 0.009 0.373 0.010 0.948
rs2374983 7 94,516,375 PPP1R9A/
PON1
0.006 0.980 0.007 0.727
rs655883 11 98,994,584 CNTN5 0.006 0.390 0.001 0.293
rs1368850 11 130,433,518 0.004 0.387 0.005 0.292
rs4943116 13 32,995,650 STARD13 0.006 0.205 0.008 0.049
rs2254191 13 45,344,403 0.007 0.425 0.004 0.116
rs1620210 13 45,759,488 C13orf18 0.001 0.161 0.004 0.068
rs2823322 21 15,814,903 0.0004 0.045 0.006 0.029
3c. FBAT: Biologic Age and Walking Speed
Trait 1 Trait 2 SNP Chr Physical 
Position
Gene Trait 1 GEE 
p-value
Trait 1 FBAT 
p-value
Trait 2 GEE 
p-value
Trait 2 FBAT 
p-value
Biologic age Walking speed rs873348 4 178,246,509 0.135 0.004 0.114 0.006
Biologic age Walking speed rs10520361* 4 178,247,037 0.074 0.006 0.054 0.005
Biologic age Walking speed rs31564 5 135,258,152 IL9 0.015 0.001 0.008 0.002
Biologic age Walking speed rs1862345 5 148,018,498 HTR4 0.172 0.0002 0.399 0.008
Biologic age Walking speed rs7844834 8 11,323,556 C8orf12|C8or
f13
0.017 0.004 0.011 0.004
Biologic age Walking speed rs952658 12 20,756,568 SLCO1C1 0.024 0.008 0.935 0.006
Biologic age Walking speed rs6487366 12 23,994,617 SOX5 0.017 0.003 0.959 0.004
Biologic age Walking speed rs7135493 12 28,134,847 0.020 0.006 0.033 0.004
Biologic age Walking speed rs10492036 12 124,728,934 0.308 0.005 0.169 0.009
Biologic age Walking speed rs1978945 13 105,641,257 0.093 0.009 0.031 0.006
Biologic age Walking speed rs2165723* 13 105,641,610 0.046 0.010 0.027 0.003
Biologic age Walking speed rs10492651* 13 105,641,634 0.083 0.009 0.023 0.001
Biologic age Walking speed rs9301112* 13 105,642,018 0.097 0.004 0.053 0.003
* r2 > 0.8 with the preceding SNP (calculated if the distance is <250,000 base pairs)
3d. GEE: Biologic Age and Walking Speed
Trait 1 Trait 2 SNP Chr Physical 
Position
Gene Trait 1 GEE 
p-value
Trait 1 FBAT
 p-value
Trait 2 GEE 
p-value
Trait 2 FBAT 
p-value
Biologic Age Walking speed rs1474827 6 134,886,011 0.007 0.746 0.000 0.233
Biologic Age Walking speed rs10231641 7 119,166,342 0.004 0.077 0.009 0.278
Biologic Age Walking speed rs310575 8 51,603,257 SNTG1 0.008 0.209 0.003 0.007
Biologic Age Walking speed rs10520603 15 84,170,955 0.009 0.008 0.003 0.050
Biologic Age Walking speed rs7166323* 15 84,171,745 0.009 0.012 0.003 0.065
Biologic Age Walking speed rs2215921 16 9,604,834 0.007 0.049 0.001 0.316
* r2 > 0.8 with the preceding SNP (calculated if the distance is <250,000 base pairs)BMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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related phenotypes and 100K SNP genotyping results
available on the web. This resource has the potential to
detect novel susceptibility genes for human longevity and
aging and to examine the relevance of promising candi-
date gene associations reported in animal models to
human aging. We describe several strategies to prioritize
SNP associations in this unique resource to enhance the
discovery of various genes and pathways that contribute
to the control of human longevity. Furthermore, FHS
investigators are part of the NIA sponsored Longevity
Consortium http://www.longevityconsortium.org which
offers the opportunity of collaboration with other investi-
gators to replicate important findings in additional
cohorts.
In our untargeted approach of ranking SNP associations
by the strength of the p-value, 2 intronic FOXO1a SNPs
were associated with age at death. One of these SNPs
(rs4943794) also was associated with biologic age by OSS
in our a priori evaluation of select candidate genes. FOXO
(forkhead box group O) transcription factors are targets of
insulin-like signaling and are involved in a diverse set of
physiological functions including DNA repair and resist-
ance to oxidative stress [33,34]. Further, FOXO plays a
role in lifespan extension in C. elegans and Drosophila [35].
Studies of this gene in humans are limited; two case-con-
trol studies have not identified an association between
FOXO1a and longevity [36,37]. However, the prospective
population-based Leiden 85-plus Study found that
FOXO1a was associated with increased mortality attribut-
able to diabetes related deaths in participants aged 85
years and older [38]. The Leiden 85-plus Study also
reported that genetic variation causing a reduction in
insulin/IGF-1 signaling resulted in improved old age sur-
vival among women [20]. However, that report examined
other genes in the insulin/insulin-like signaling pathway
and did not specifically examine FOXO1a. Finally, the
untargeted approach to SNP selection also identified a
SNP near FOXO3a associated with age at natural meno-
pause. This gene has been implicated in oocyte death,
Table 4: All Significant SNP Associations with Selected Longevity Candidate Genes* (FBAT or GEE p-value < 0.01)
Trait Gene SNP Chr Physical 
Position
FBAT p-value GEE p-value SNP function SNP position relative
to gene (up to 60 kb)
Age at death FOXO1a rs4943794 13 40,071,408 0.068 0.00028  Intron in
rs10507486 13 40,084,501 0.043 0.00013  Intron in
GAPDH† rs4764600 12 6,472,241 0.833 0.005 Locus/intron near
KL rs683907 13 32,522,175 0.009 0.507 Intron in
rs687045 13 32,522,889 0.007 0.712 Intron in
LEPR rs1475398 1 65,695,278 0.069 0.005 Untranslated in
rs1343981 1 65,757,349 0.031 0.006 Intron in
rs10493379 1 65,757,948 0.015 0.004 Intron in
rs2154380 1 65,769,462 0.004 0.003 Intron in
rs6669117 1 65,773,093 0.050 0.007 Intron in
PON1 rs2374983 7 94,516,375 0.980 0.006 Intron near
PSEN1 rs362356 14 72,708,382 0.005 0.130 Intron in
SOD2 rs911847 6 160,039,379 0.358 0.005 Unknown near
WRN‡ rs2543600 8 30,969,282 0.182 4.2 × 10-6 Unknown near
Morbidity-free survival at age 65 GHR rs719756 5 42,761,386 0.003 0.676 Unknown near
LEPR rs1171278 1 65,700,167 0.042 0.003 Untranslated in
rs3790426 1 65,755,040 0.460 0.002 Intron in
MORF4L1 rs1383636 15 76,893,275 0.458 0.007 Unknown near
PON1 rs2374983 7 94,516,375 0.727 0.007 Intron near
rs854523 7 94,542,884 0.850 0.007 Intron in
PTH rs10500784 11 13,530,401 0.010 0.990 Unknown near
WRN‡ rs2725369 8 30,970,566 0.113 0.003 Unknown near
Biologic Age by OSS FOXO1a rs1923249 13 40,041,881 0.006 0.004 Intron in
rs4943794 13 40,071,408 0.009 0.016 Intron in
HSPA9 rs256014 5 137,930,983 0.101 0.005 Intron in
LASS6 rs1002666 2 169,303,525 0.001 0.008 Intron in
SOD2 rs911847 6 160,039,379 0.024 0.009 Unknown near
TLR4 rs1927914 9 117,544,279 0.007 0.401 Locus near
Walking speed ESR1 rs9322361 6 152,551,257 0.124 0.0089  Intron in
LASS6 rs6433083 2 169,324,821 0.232 0.006 Intron in
NR3C1 rs2918418 5 142,703,566 0.005 0.081 Intron in
rs10515522 5 142,738,587 0.004 0.084 Intron in
SOD1 rs2833485 21 32,000,796 0.008 0.507 Locus/intron in
TERF2 rs728546 16 68,013,029 0.0045 0.533 Unknown near
FASLG rs6700734 1 169,362,468 0.003 0.029 Intron in
*79 genes identified from NCBI, SAGE ke, and GenAge databases; 12 genes with no SNPs on 100K chip; 67 genes with 1–45 SNPs on 100K chip; LGV1 2036 SNPs on 100K 
chip, results for this region available on the web
†The most strongly associated SNP near GAPDH is actually closer to MRPL51
‡The most strongly associated SNP near WRN is actually closer to PURGBMC Medical Genetics 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2350/8/S1/S13
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depletion of functioning ovarian follicles, and infertility
in mice [39,40] and thus represents a plausible candidate
gene for menopause. Most positive common gene variant-
disease association studies have failed replication [41]
including reports on exceptional longevity. Haplotype-
based fine mapping of the region on chromosome 4
linked to human longevity initially suggested the MTP
gene, a gene important in lipoprotein synthesis, was asso-
ciated with longevity [21]. However, this association
failed replication in a French cohort of long-lived individ-
uals and subsequent case-control studies of nonagenari-
ans [22,42]. Beekman, et al [43] found neither linkage to
chromosome 4 nor association with the MTP gene and
longevity among nonagenarians in the Leiden Longevity
Study. Meta-analyses implicated admixture of the control
sample in the original report as an explanation for the pre-
sumed false-positive association. Thus, our findings are
hypothesis generating and their importance can not be
determined without evidence of consistent replication in
other populations.
We examined pleiotropic effects by identifying SNP asso-
ciations across two pairs of related traits. One SNP near
PON1 emerged as associated with both age at death and
morbidity-free survival. Surprisingly, there were relatively
few SNPs associated with both traits; prior work had sug-
gested that longevity per se and healthy aging may share
common genetic pathways [11,12]. However, morbidity-
free survival was measured at age 65 years, it is possible
that as our participants age morbidity-free survival
defined at age 75 or 85 years will share additional SNP
associations with our longevity trait, age at death. A SNP
near SOX5, a gene potentially related to musculoskeletal
function was associated with both biologic age by OSS
and walking speed.
Our strategy of selecting SNPs in candidate genes and
regions previously reported to be associated with longev-
ity yielded interesting findings. For age at death, we iden-
tified SNPs in or near several genes including KL, LEPR,
PON1, SOD2, and WRN. Defects in the WRN gene are the
cause of Werner Syndrome, an autosomal recessive disor-
der characterized by premature aging. A longitudinal
study of ageing Danish twins recently reported a possible
association between a successful aging trait and 3 SNPs in
the WRN gene [44]. We were unable to determine if our
SNP (rs2725369) was in LD with the SNPs in the prior
report because the SNPs were not included in HapMap.
Mutations in the KL (Klotho) gene in the mouse lead to a
syndrome resembling human aging [45-47]. There has
been one report linking a functional variant of the KL gene
to human longevity [15]. Thus, results from this GWAS
may direct resources to the most relevant candidate genes
and pathways for further investigation in humans.
Several important limitations merit comment. First, we
acknowledge that there may be a survival bias as partici-
pants in this sample had to survive to provide DNA (first
systematic DNA collection began 1995) and hence are
likely healthier than the full FHS sample. To ameliorate
this issue, we adjusted for covariates using the full Fram-
ingham sample, and used the residual traits for the subset
of individuals genotyped using the 100K Affymetrix Gene-
Chip to test for association with the SNPs using linear
regression models. Residual traits from Cox and logistic
models typically are not ideally distributed for linear
regression models, but our adjustment method using the
full sample precludes the testing of SNP associations with
age at death and morbidity-free survival using Cox and
logistic models. Second, the 100K Affymetrix GeneChip
provides limited coverage of the genome; many of our a
priori candidate genes did not have any SNP coverage on
the chip. For example, several genes that have been stud-
ied in model organisms or even in humans such as ACE,
Lamin A, SIRT2 and SIRT3, had no SNPs within 60 kb of
the gene on the 100K Affymetrix GeneChip. However,
genotyping is near-complete for the NHLBI funded 550 K
genome-wide scan on all FHS participants. This will ena-
ble deeper exploration of our initial 100K SNP associa-
tions in a larger sample with denser coverage of the
genome. Third, in this analysis we did not examine epista-
sis or gene-environment interactions which may modify
the associations in this study. Importantly, this study is
hypothesis generating. Our findings need to be replicated
in other samples.
Conclusion
In summary, the untargeted genome-wide approach to
detect genetic associations with longevity and aging traits
provides an opportunity to identify novel biologic path-
ways related to lifespan control. GWAS also have the
potential to direct investigators of human aging to the
most promising candidate gene associations and biologic
pathways reported to regulate lifespan in animal models.
Enhancing our understanding of the mechanisms respon-
sible for aging may in turn identify directions for health
promotion and disease prevention efforts in middle-aged
and older adults so that older persons can enjoy more
time in good health. These data generate hypotheses
regarding novel biologic pathways contributing to longev-
ity and healthy aging and serve as a resource for replica-
tion of findings from other population-based samples.
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